Comparative Pharmacology
Head-to-head clinical analysis: TESTODERM TTS versus TESTOSTERONE CYPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTODERM TTS versus TESTOSTERONE CYPIONATE.
TESTODERM TTS vs TESTOSTERONE CYPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone is an androgen receptor agonist. It binds to and activates androgen receptors, leading to changes in gene expression that promote the development and maintenance of male secondary sexual characteristics, anabolic effects, and spermatogenesis.
Testosterone cypionate is a synthetic androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development. It also suppresses gonadotropin release via negative feedback.
Apply 4 mg (one 4 mg/24 hr system) or 6 mg (one 6 mg/24 hr system) transdermally once daily, applied to clean, dry, intact skin on the back, abdomen, thighs, or upper arms. Rotate application sites with an interval of at least 7 days.
Intramuscular injection of 50-400 mg every 2-4 weeks, typically 200 mg every 2 weeks or 400 mg every 4 weeks.
None Documented
None Documented
The terminal elimination half-life of testosterone administered transdermally is approximately 1.5–2 hours. This short half-life requires daily application of the patch to maintain therapeutic levels.
Approximately 8 days (terminal elimination half-life of testosterone cypionate after intramuscular injection; due to slow release from oil depot, effective half-life in muscle is ~8 days with a longer terminal phase up to 3 weeks)
Testosterone is excreted primarily in the urine as glucuronide and sulfate conjugates (approximately 90%), with about 6% excreted in feces via bile. Less than 1% is excreted unchanged.
Renal (90% as glucuronide and sulfate conjugates), fecal (10%)
Category C
Category D/X
Androgen
Androgen